FDA
-
-
-
-
-
-
-
BioArctic Interim Report for the period January - March 2026
-
-
-
-
-
-
-
Interim Report for the period July - September 2025: BioArctic
-
-
-
-
-
-
-
The European Commission refers lecanemab decision to Appeal Committee
-
-
-
-
-
-
-
CHMP has adopted a negative opinion on lecanemab for the EU
-
-
-
-
-
-
-
The European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
-
-
329,625 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

